Inhibition of NGLY1 Inactivates the Transcription Factor Nrf1 and Potentiates Proteasome Inhibitor Cytotoxicity

[Image: see text] Proteasome inhibitors are used to treat blood cancers such as multiple myeloma (MM) and mantle cell lymphoma. The efficacy of these drugs is frequently undermined by acquired resistance. One mechanism of proteasome inhibitor resistance may involve the transcription factor Nuclear F...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomlin, Frederick M., Gerling-Driessen, Ulla I. M., Liu, Yi-Chang, Flynn, Ryan A., Vangala, Janakiram R., Lentz, Christian S., Clauder-Muenster, Sandra, Jakob, Petra, Mueller, William F., Ordoñez-Rueda, Diana, Paulsen, Malte, Matsui, Naoko, Foley, Deirdre, Rafalko, Agnes, Suzuki, Tadashi, Bogyo, Matthew, Steinmetz, Lars M., Radhakrishnan, Senthil K., Bertozzi, Carolyn R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2017
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5704294/
https://www.ncbi.nlm.nih.gov/pubmed/29202016
http://dx.doi.org/10.1021/acscentsci.7b00224

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5704294/
https://www.ncbi.nlm.nih.gov/pubmed/29202016
http://dx.doi.org/10.1021/acscentsci.7b00224

Ejemplares similares